Renal Therapeutics Market Size, Share And Global Trend By Application (Chronic kidney disease, Diabetes, Kidney stone disease, Kidney failure, Others), By Drug Class (Angiotensin-II receptor blockers, ACE Inhibitors, Calcium channel blockers, Beta-blockers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
In April 2019, Merck Sharp & Dohme Corp. received U.S Food and Drug Administration approval for the drug KEYTRUDA (pembrolizumab) for the treatment of renal cell carcinoma. According to recent studies by the National Kidney Foundation, an estimated 10% of the population globally is suffering from chronic kidney disease, and millions die annually due to lack of access to inexpensive treatment. One of the major factors leading to rise in renal disorders worldwide is the increasing prevalence of diabetes. Several novel drugs in development by key market players to treat renal disease are anticipated to fuel the global renal therapeutics market.
The global renal therapeutics market is expected to grow rapidly during the forecast period, owing to the increasing incidence & prevalence of kidney diseases and rise in the aging population. Initiatives taken by key companies in the investment of the development of the new drugs and therapies for the treatment of the renal failure combined with various pipeline drugs is estimated to lead to the growth of the global renal therapeutics market.
To gain extensive insights into the market, Request for Customization
However, the high cost of the treatment and side effects of the different treatment are some of the major restraining factors for the growth of the global renal therapeutics market.
Key Players Covered
Some of the major companies that are present in the global renal therapeutics market Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Vifor Pharma Inc., AstraZeneca, Novartis AG, Pfizer Inc., Bayer AG, and Johnson & Johnson Services, Inc. others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Application | · Chronic kidney disease · Diabetes · Kidney stone disease · Kidney failure · Others |
By Drug Class | · Angiotensin-II receptor blockers · ACE Inhibitors · Calcium channel blockers · Beta-blockers · Others |
By Distribution Channel | · Hospital Pharmacies · Retail Pharmacies · Online Pharmacies |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Among the application segmentation, chronic kidney disease is anticipated to register highest market share owing to the high prevalence of this disease.
Key Insights
Overview of the prevalence of kidney diseases
Pipeline analysis
Regulatory scenario for key countries
Key mergers and acquisitions
Regional Analysis
The global renal therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share in the global market in 2018, owing to the rising prevalence of chronic diseases and increase in number of surgical procedures in the treatment of kidney diseases, cancer and among others. Additionally, established healthcare infrastructure in the developed countries of North America and Europe is anticipated to lead to an increase in demand for new and advanced renal therapeutics. Asia Pacific expected to register comparative higher CAGR from 2019-2026 due to rising prevalence of kidney diseases, developing healthcare infrastructure, and growing emphasis by healthcare organizations and government towards the development of new drugs, expected to drive the demand for renal therapeutics in the region from 2019-2026.
Key Industry Developments
- In March 2019, Janssen Pharmaceuticals, Inc. submitted supplemental New Drug Application (sNDA) to the U.S FDA for canagliflozin, the first diabetic drug indicated for the treatment of chronic kidney disease in type 2 diabetic patients.
- In February 2019, AstraZeneca announced that the U.S FDA approved the expanded indication of dapagliflozin for treatment of moderate renal impairment.
- In June 2018, the U.S FDA Mircera, a product manufacture by Vifor Pharma Inc. for the treatment of anaemia associated with chronic kidney disease.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
